KDM6B and acute myeloid leukemia: Nevertheless, JMJD3 knockdown in five primary AML blastic samples (one M2 without AE, one M3, one M4, and two M5) decreased CD11b level in four cases except one M5 but not significantly influenced their survival status (Supplementary Fig. 2e, h), indicating a genuine regulatory role of JMJD3 on the differentiation status of AML blasts.